Edition:
United Kingdom

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

13.46USD
18 Jun 2018
Change (% chg)

$0.23 (+1.74%)
Prev Close
$13.23
Open
$13.18
Day's High
$13.47
Day's Low
$12.72
Volume
82,758
Avg. Vol
49,884
52-wk High
$17.11
52-wk Low
$5.07

Chart for

About

Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It... (more)

Overall

Beta: 0.05
Market Cap(Mil.): $229.69
Shares Outstanding(Mil.): 24.20
Dividend: --
Yield (%): --

Financials

  SVRA.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -5.74 -- --
ROI: -43.82 1.56 14.38
ROE: -65.80 2.43 16.07

BRIEF-Savara Reports Q1 Loss Per Share $0.88

* SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

09 May 2018

BRIEF-Savara Reports Q4 Loss Per Share $0.23

* SAVARA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

14 Mar 2018

BRIEF-Savara Initiates Phase 2A Clinical Study Of Molgradex For The Treatment Of Ntm Lung Infection

* SAVARA INITIATES PHASE 2A CLINICAL STUDY OF MOLGRADEX FOR THE TREATMENT OF NTM LUNG INFECTION Source text for Eikon: Further company coverage:

13 Mar 2018

BRIEF-Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S.

* SAVARA ANNOUNCES IND APPROVAL FOR EXPANSION OF MOLGRADEX PHASE 3 STUDY INTO U.S.

12 Feb 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.16 -0.20
Johnson & Johnson (JNJ.N) $121.32 -1.29
Roche Holding Ltd. (ROG.S) CHF210.00 --
Roche Holding Ltd. (RO.S) CHF214.40 --
Sanofi SA (SASY.PA) €68.25 --
GlaxoSmithKline plc (GSK.L) 1,552.80 --

Earnings vs. Estimates